IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Advisory Alpha LLC

Advisory Alpha LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 44.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,137 shares of the medical research company’s stock after buying an additional 656 shares during the quarter. Advisory Alpha LLC’s holdings in IQVIA were worth $452,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of IQV. NEOS Investment Management LLC lifted its holdings in shares of IQVIA by 70.8% in the 4th quarter. NEOS Investment Management LLC now owns 2,590 shares of the medical research company’s stock valued at $599,000 after buying an additional 1,074 shares during the period. Goldman Sachs Group Inc. raised its holdings in IQVIA by 21.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 837,865 shares of the medical research company’s stock worth $193,865,000 after purchasing an additional 148,568 shares during the period. Capital Research Global Investors raised its holdings in IQVIA by 42.2% in the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after purchasing an additional 592,372 shares during the period. Tower Research Capital LLC TRC raised its holdings in IQVIA by 171.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 26,868 shares of the medical research company’s stock worth $6,217,000 after purchasing an additional 16,967 shares during the period. Finally, 1832 Asset Management L.P. raised its holdings in IQVIA by 5.6% in the 4th quarter. 1832 Asset Management L.P. now owns 149,737 shares of the medical research company’s stock worth $34,646,000 after purchasing an additional 8,000 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on IQV shares. Robert W. Baird upped their price target on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a report on Friday, September 20th. Barclays upped their price target on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their price objective on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and cut their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Finally, Evercore ISI boosted their price objective on IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.00.

IQVIA Trading Down 2.4 %

IQV opened at $231.37 on Wednesday. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The stock has a market capitalization of $42.18 billion, a PE ratio of 31.61, a P/E/G ratio of 2.25 and a beta of 1.49. The business’s 50 day moving average price is $241.17 and its 200 day moving average price is $232.92. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the firm earned $2.22 earnings per share. The firm’s revenue was up 2.3% compared to the same quarter last year. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.